Preoperative liquid biopsy for EGFR-mutated detection at diagnostic in early-stage non-small cell lung cancer: real-world experience of a single centre
Adjuvant osimertinib is the standard of care for patients with resected stage IB-IIIA EGFR -mutated non-squamous non-small cell lung cancer (NS-NSCLC).1 Consequently, preoperative EGFR status assessment is essential to identify candidates for adjuvant osimertinib ( EGFR -mutated patients) versus neoadjuvant immunotherapy ( EGFR wild-type (WT) patients).1 EGFR mutations are detected in DNA from tumour tissue biopsy via next-generation sequencing (NGS) or single-gene sequencing.1 However, obtaining adequate tumour tissue can be challenging due to tumour inaccessibility or patient condition. Alternatively, liquid biopsies (LB) allow detection of mutations in cell-free DNA (cfDNA) from blood, offering a rapid and minimally invasive method that may also better capture tumour heterogeneity.2 However, current data on preoperative LB use for EGFR status evaluation in early-stage NSCLC are limited. Multiplex droplet digital PCR (ddPCR) provides a rapid, cost-effective and sensitive option for d
